Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2): Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein expression

Wu Huei Hsu, Ruoh Fang Yen, Chia Hung Kao, Shih Chih Shiun, Nan Yung Hsu, Cheng Chieh Lin, Cheng Chun Lee

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: The aim of this study was to compare technetium-99m methoxyisobutylisonitrile (Tc-MIBI) chest single photon emission computed tomography (SPECT) results, immunohistochemical analyses of P-glycoprotein (Pgp) expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 30 patients with stage IIIb or IV NSCLC were enrolled in this study. Early chest SPECT was performed 10 min after intravenous injection of Tc-MIBI. Tc-MIBI chest SPECT images were qualitatively interpreted. Early tumor-to-normal lung ratios (T/NL) were calculated quantitatively. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100%) cases with good response and negative Pgp expression had positive results of early Tc-MIBI chest SPECT. Ten of 15 (67%) cases with poor response and positive Pgp expression had negative results of early Tc-MIBI chest SPECT. These early T/NL ratios (3.3 ± 0.8 for the 15 patients with good response and 2.0 ± 0.2 for the 5 patients with poor response) in lung cancer could be detected on early Tc-MIBI chest SPECT. The difference was significant (p <0.05) by an independent Student t test. However, no significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between the good and poor response groups. Conclusion: Early Tc-MIBI chest SPECT can be used to understand the Pgp expression in NSCLC and to quickly predict chemotherapy response to paclitaxel.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalOncology
Volume63
Issue number2
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

P-Glycoprotein
Paclitaxel
Single-Photon Emission-Computed Tomography
Non-Small Cell Lung Carcinoma
Thorax
Drug Therapy
Therapeutics
Neoplasms
Lung
technetium 99m methoxyisobutylisonitrile
Intravenous Injections
Weight Loss
Lung Neoplasms
Body Weight
Students
Biopsy

Keywords

  • Chemotherapy
  • Non-small-cell lung cancer
  • P-Glycoprotein
  • Single photon emission computed tomography
  • Technetium-99m methoxyisobutylisonitrile

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2) : Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein expression. / Hsu, Wu Huei; Yen, Ruoh Fang; Kao, Chia Hung; Shiun, Shih Chih; Hsu, Nan Yung; Lin, Cheng Chieh; Lee, Cheng Chun.

In: Oncology, Vol. 63, No. 2, 2002, p. 173-179.

Research output: Contribution to journalArticle

@article{5c4515c7e9ed4e5bbb2d2cc38b353335,
title = "Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2): Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein expression",
abstract = "Objective: The aim of this study was to compare technetium-99m methoxyisobutylisonitrile (Tc-MIBI) chest single photon emission computed tomography (SPECT) results, immunohistochemical analyses of P-glycoprotein (Pgp) expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 30 patients with stage IIIb or IV NSCLC were enrolled in this study. Early chest SPECT was performed 10 min after intravenous injection of Tc-MIBI. Tc-MIBI chest SPECT images were qualitatively interpreted. Early tumor-to-normal lung ratios (T/NL) were calculated quantitatively. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100{\%}) cases with good response and negative Pgp expression had positive results of early Tc-MIBI chest SPECT. Ten of 15 (67{\%}) cases with poor response and positive Pgp expression had negative results of early Tc-MIBI chest SPECT. These early T/NL ratios (3.3 ± 0.8 for the 15 patients with good response and 2.0 ± 0.2 for the 5 patients with poor response) in lung cancer could be detected on early Tc-MIBI chest SPECT. The difference was significant (p <0.05) by an independent Student t test. However, no significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between the good and poor response groups. Conclusion: Early Tc-MIBI chest SPECT can be used to understand the Pgp expression in NSCLC and to quickly predict chemotherapy response to paclitaxel.",
keywords = "Chemotherapy, Non-small-cell lung cancer, P-Glycoprotein, Single photon emission computed tomography, Technetium-99m methoxyisobutylisonitrile",
author = "Hsu, {Wu Huei} and Yen, {Ruoh Fang} and Kao, {Chia Hung} and Shiun, {Shih Chih} and Hsu, {Nan Yung} and Lin, {Cheng Chieh} and Lee, {Cheng Chun}",
year = "2002",
doi = "10.1159/000063811",
language = "English",
volume = "63",
pages = "173--179",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "2",

}

TY - JOUR

T1 - Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2)

T2 - Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein expression

AU - Hsu, Wu Huei

AU - Yen, Ruoh Fang

AU - Kao, Chia Hung

AU - Shiun, Shih Chih

AU - Hsu, Nan Yung

AU - Lin, Cheng Chieh

AU - Lee, Cheng Chun

PY - 2002

Y1 - 2002

N2 - Objective: The aim of this study was to compare technetium-99m methoxyisobutylisonitrile (Tc-MIBI) chest single photon emission computed tomography (SPECT) results, immunohistochemical analyses of P-glycoprotein (Pgp) expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 30 patients with stage IIIb or IV NSCLC were enrolled in this study. Early chest SPECT was performed 10 min after intravenous injection of Tc-MIBI. Tc-MIBI chest SPECT images were qualitatively interpreted. Early tumor-to-normal lung ratios (T/NL) were calculated quantitatively. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100%) cases with good response and negative Pgp expression had positive results of early Tc-MIBI chest SPECT. Ten of 15 (67%) cases with poor response and positive Pgp expression had negative results of early Tc-MIBI chest SPECT. These early T/NL ratios (3.3 ± 0.8 for the 15 patients with good response and 2.0 ± 0.2 for the 5 patients with poor response) in lung cancer could be detected on early Tc-MIBI chest SPECT. The difference was significant (p <0.05) by an independent Student t test. However, no significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between the good and poor response groups. Conclusion: Early Tc-MIBI chest SPECT can be used to understand the Pgp expression in NSCLC and to quickly predict chemotherapy response to paclitaxel.

AB - Objective: The aim of this study was to compare technetium-99m methoxyisobutylisonitrile (Tc-MIBI) chest single photon emission computed tomography (SPECT) results, immunohistochemical analyses of P-glycoprotein (Pgp) expression and response to paclitaxel in non-small-cell lung cancer (NSCLC). Methods: Before chemotherapy with paclitaxel, 30 patients with stage IIIb or IV NSCLC were enrolled in this study. Early chest SPECT was performed 10 min after intravenous injection of Tc-MIBI. Tc-MIBI chest SPECT images were qualitatively interpreted. Early tumor-to-normal lung ratios (T/NL) were calculated quantitatively. Immunohistochemical analyses were performed on multiple nonconsecutive sections of the biopsy specimens to determine Pgp expression. Chemotherapy response was evaluated in the third month after completion of treatment by clinical and radiological methods. Results: All 15 (100%) cases with good response and negative Pgp expression had positive results of early Tc-MIBI chest SPECT. Ten of 15 (67%) cases with poor response and positive Pgp expression had negative results of early Tc-MIBI chest SPECT. These early T/NL ratios (3.3 ± 0.8 for the 15 patients with good response and 2.0 ± 0.2 for the 5 patients with poor response) in lung cancer could be detected on early Tc-MIBI chest SPECT. The difference was significant (p <0.05) by an independent Student t test. However, no significant differences were found for other prognostic factors (age, sex, body weight loss, performance status, tumor cell type, and tumor stage) between the good and poor response groups. Conclusion: Early Tc-MIBI chest SPECT can be used to understand the Pgp expression in NSCLC and to quickly predict chemotherapy response to paclitaxel.

KW - Chemotherapy

KW - Non-small-cell lung cancer

KW - P-Glycoprotein

KW - Single photon emission computed tomography

KW - Technetium-99m methoxyisobutylisonitrile

UR - http://www.scopus.com/inward/record.url?scp=0036381377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036381377&partnerID=8YFLogxK

U2 - 10.1159/000063811

DO - 10.1159/000063811

M3 - Article

C2 - 12239453

AN - SCOPUS:0036381377

VL - 63

SP - 173

EP - 179

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -